BKEMV

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS Eculizumab products, complement inhibitors, increase the risk of serious infections caused by Neisseria meningitidis [see Warnings and Precautions (5.1) ] . Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early. Complete or update vaccination for meningococcal bacteria (for serogroups A, C, W, Y, and B) at least 2 weeks prior to the first dose of BKEMV, unless the risks of delaying therapy with BKEMV outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against meningococcal bacteria in patients receiving a complement inhibitor. See Warnings and Precautions (5.1) for additional guidance on the management of the risk of serious infections caused by meningococcal bacteria. Patients receiving eculizumab products are at increased risk for invasive disease caused by Neisseria meningitidis , even if they develop antibodies following vaccination. Monitor patients for early signs and symptoms of serious meningococcal infections and evaluate immediately if infection is suspected. Because of the risk of serious meningococcal infections, BKEMV is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called BKEMV REMS [see Warnings and Precautions (5.2) ] . WARNING: SERIOUS MENINGOCOCCAL INFECTIONS See full prescribing information for complete boxed warning Eculizumab products increase the risk of serious and life-threatening infections caused by Neisseria meningitidis . Complete or update meningococcal vaccination at least 2 weeks prior to the first dose of BKEMV, unless the risks of delaying BKEMV outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients receiving a complement inhibitor. ( 5.1 ) Patients receiving eculizumab products are at increased risk for invasive disease caused by N. meningitidis , even if they develop antibodies following vaccination. Monitor patients for early signs and symptoms of meningococcal infections and evaluate immediately if infection is suspected. ( 5.1 ) BKEMV is available only through a restricted program called BKEMV REMS. ( 5.2 )

5 WARNINGS AND PRECAUTIONS Use caution when administering BKEMV to patients with any other systemic infection. ( 5.3 ) Infusion-Related Reactions: Monitor patients during infusion, interrupt for reactions, and institute appropriate supportive measures. ( 5.6 ) 5.1 Serious Meningococcal Infections Eculizumab products, complement inhibitors, increase a patient's susceptibility to serious, life-threatening, or fatal infections caused by meningococcal bacteria (septicemia and/or meningitis) in any serogroup, including non-groupable strains. Life-threatening and fatal meningococcal infections have occurred in both vaccinated and unvaccinated patients treated with complement inhibitors. The initiation of BKEMV treatment is contraindicated in patients with unresolved serious Neisseria meningitidis infection. Complete or update meningococcal vaccination (for serogroups A, C, W, Y and B) at least 2 weeks prior to administration of the first dose of BKEMV, according to current ACIP recommendations for patients receiving a complement inhibitor. Revaccinate patients in accordance with ACIP recommendations considering the duration of therapy with BKEMV. Note that ACIP recommends an administration schedule in patients receiving complement inhibitors that differs from the administration schedule in the vaccine prescribing information. If urgent BKEMV therapy is indicated in a patient who is not up to date with meningococcal vaccines according to ACIP recommendations, provide the patient with antibacterial drug prophylaxis and administer meningococcal vaccines as soon as possible. Various durations and regimens of antibacterial drug prophylaxis have been considered, but the optimal durations and drug regimens for prophylaxis and their efficacy have not been studied in unvaccinated or vaccinated patients receiving complement inhibitors, including eculizumab products. The benefits and risks of treatment with BKEMV, as well as the benefits and risks of antibacterial drug prophylaxis in unvaccinated or vaccinated patients, must be considered against the known risks for serious infections caused by Neisseria meningitidis . Vaccination does not eliminate the risk of serious meningococcal infections, despite development of antibodies following vaccination. Closely monitor patients for early signs and symptoms of meningococcal infection and evaluate patients immediately if infection is suspected. Inform patients of these signs and symptoms and instruct patients to seek immediate medical care if these signs and symptoms occur. Promptly treat known infections. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early. Consider interruption of BKEMV in patients who are undergoing treatment for serious meningococcal infection, depending on the risks of interrupting treatment in the disease being treated. BKEMV is available only through a restricted program under a REMS [see Warnings and Precautions (5.2) ] . 5.2 BKEMV REMS BKEMV is available only through a restricted program under a REMS called BKEMV REMS, because of the risk of serious meningococcal infections [see Warnings and Precautions (5.1) ] . Notable requirements of the BKEMV REMS include the following: Prescribers must enroll in the REMS. Prescribers must counsel patients about the risk of serious meningococcal infection. Prescribers must provide the patients with the REMS educational materials. Prescribers must assess patient vaccination status for meningococcal vaccines (against serogroups A, C, W, Y and B) and vaccinate if needed according to current ACIP recommendations 2 weeks prior to the first dose of BKEMV. Prescribers must provide a prescription for antibacterial drug prophylaxis if treatment must be started urgently and the patient is not up to date with meningococcal vaccines according to current ACIP recommendations at least two weeks prior to the first dose of BKEMV. Healthcare settings and pharmacies that dispense BKEMV must be certified in the REMS and must verify prescribers are certified. Patients must receive counseling from the prescriber about the need to receive meningococcal vaccines per ACIP recommendations, the need to take antibiotics as directed by the prescriber, and the signs and symptoms of meningococcal infection. Patients must be instructed to carry the Patient Safety Card with them at all times during and for 3 months following treatment with BKEMV. Further information is available at www.BKEMVREMS.com or 1-866-718-6927. 5.3 Other Infections Serious infections with Neisseria species (other than Neisseria meningitidis ), including disseminated gonococcal infections, have been reported. Eculizumab products block terminal complement activation; therefore, patients may have increased susceptibility to infections, especially with encapsulated bacteria, such as infections with Neisseria meningitidis but also Streptococcus pneumoniae , Haemophilus influenzae , and to a lesser extent, Neisseria gonorrhoeae . Additionally, Aspergillus infections have occurred in immunocompromised and neutropenic patients. Children treated with eculizumab products may be at increased risk of developing serious infections due to Streptococcus pneumoniae and Haemophilus influenzae type b (Hib). Administer vaccinations for the prevention of Streptococcus pneumoniae and Haemophilus influenzae type b (Hib) infections according to ACIP recommendations. Patients receiving eculizumab products are at increased risk for infections due to these organisms, even if they develop antibodies following vaccination. 5.4 Monitoring Disease Manifestations after BKEMV Discontinuation Treatment Discontinuation for PNH Monitor patients after discontinuing BKEMV for at least 8 weeks to detect hemolysis. Treatment Discontinuation for aHUS After discontinuing BKEMV, monitor patients with aHUS for signs and symptoms of thrombotic microangiopathy (TMA) complications for at least 12 weeks. In aHUS clinical trials, 18 patients (5 in the prospective studies) discontinued eculizumab treatment. TMA complications occurred following a missed dose in 5 patients, and eculizumab was reinitiated in 4 of these 5 patients. Clinical signs and symptoms of TMA include changes in mental status, seizures, angina, dyspnea, or thrombosis. In addition, the following changes in laboratory parameters may identify a TMA complication: occurrence of two, or repeated measurement of any one of the following: a decrease in platelet count by 25% or more compared to baseline or the peak platelet count during BKEMV treatment; an increase in serum creatinine by 25% or more compared to baseline or nadir during BKEMV treatment; or, an increase in serum LDH by 25% or more over baseline or nadir during BKEMV treatment. If TMA complications occur after BKEMV discontinuation, consider reinstitution of BKEMV treatment, plasma therapy [plasmapheresis, plasma exchange, or fresh frozen plasma infusion (PE/PI)], or appropriate organ-specific supportive measures. 5.5 Thrombosis Prevention and Management The effect of withdrawal of anticoagulant therapy during eculizumab products treatment has not been established. Therefore, treatment with eculizumab products should not alter anticoagulant management. 5.6 Infusion-Related Reactions Administration of eculizumab products may result in infusion-related reactions, including anaphylaxis or other hypersensitivity reactions. In clinical trials, no patients experienced an infusion-related reaction which required discontinuation of eculizumab. Interrupt BKEMV infusion and institute appropriate supportive measures if signs of cardiovascular instability or respiratory compromise occur.

6 ADVERSE REACTIONS The following serious adverse reactions are discussed in greater detail in other sections of the labeling: Serious Meningococcal Infections [see Warnings and Precautions (5.1) ] Other Infections [see Warnings and Precautions (5.3) ] Monitoring Disease Manifestations after BKEMV Discontinuation [see Warnings and Precautions (5.4) ] Thrombosis Prevention and Management [see Warnings and Precautions (5.5) ] Infusion-Related Reactions [see Warnings and Precautions (5.6) ] The most frequently reported adverse reactions in the PNH randomized trial (≥ 10% overall and greater than placebo) are: headache, nasopharyngitis, back pain, and nausea. ( 6.1 ) The most frequently reported adverse reactions in aHUS single arm prospective trials (≥ 20%) are: headache, diarrhea, hypertension, upper respiratory infection, abdominal pain, vomiting, nasopharyngitis, anemia, cough, peripheral edema, nausea, urinary tract infections, pyrexia. ( 6.1 ) The most frequently reported adverse reaction in the gMG placebo-controlled clinical trial (≥ 10%) in adult patients is musculoskeletal pain. ( 6.1 ) The most frequently reported adverse reactions in the NMOSD placebo-controlled trial (≥ 10%) are: upper respiratory infection, nasopharyngitis, diarrhea, back pain, dizziness, influenza, arthralgia, pharyngitis, and contusion. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Amgen Medical Information at 1-800-77-AMGEN (1-800-772-6436) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Meningococcal infections are the most important adverse reactions experienced by patients receiving eculizumab. In PNH clinical studies, two patients experienced meningococcal sepsis. Both patients had previously received a meningococcal vaccine. In clinical studies among patients without PNH, meningococcal meningitis occurred in one unvaccinated patient. Meningococcal sepsis occurred in one previously vaccinated patient enrolled in the retrospective aHUS study during the post-study follow-up period [see Warnings and Precautions (5.1) ] . PNH The data described below reflect exposure to eculizumab in 196 adult patients with PNH, age 18-85, of whom 55% were female. All had signs or symptoms of intravascular hemolysis. Eculizumab was studied in a placebo-controlled clinical study (PNH Study 1, in which 43 patients received eculizumab and 44, placebo); a single arm clinical study (PNH Study 2); and a long-term extension study (E05-001). One hundred and eighty two patients were exposed for greater than one year. All patients received the recommended eculizumab dose regimen. Table 5 summarizes the adverse reactions that occurred at a numerically higher rate in the eculizumab group than the placebo group and at a rate of 5% or more among patients treated with eculizumab. Table 5: Adverse Reactions Reported in 5% or More of Eculizumab Treated Patients with PNH and Greater than Placebo in the Controlled Clinical Study Reaction Eculizumab (N = 43) N (%) Placebo (N = 44) N (%) Headache 19 (44) 12 (27) Nasopharyngitis 10 (23) 8 (18) Back pain 8 (19) 4 (9) Nausea 7 (16) 5 (11) Fatigue 5 (12) 1 (2) Cough 5 (12) 4 (9) Herpes simplex infections 3 (7) 0 Sinusitis 3 (7) 0 Respiratory tract infection 3 (7) 1 (2) Constipation 3 (7) 2 (5) Myalgia 3 (7) 1 (2) Pain in extremity 3 (7) 1 (2) Influenza-like illness 2 (5) 1 (2) In the placebo-controlled clinical study, serious adverse reactions occurred among 4 (9%) patients receiving eculizumab and 9 (21%) patients receiving placebo. The serious reactions included infections and progression of PNH. No deaths occurred in the study and no patients receiving eculizumab experienced a thrombotic event; one thrombotic event occurred in a patient receiving placebo. Among 193 patients with PNH treated with eculizumab in the single arm, clinical study or the follow-up study, the adverse reactions were similar to those reported in the placebo-controlled clinical study. Serious adverse reactions occurred among 16% of the patients in these studies. The most common serious adverse reactions were: viral infection (2%), headache (2%), anemia (2%), and pyrexia (2%). aHUS The safety of eculizumab therapy in patients with aHUS was evaluated in four prospective, single-arm studies, three in adult and adolescent patients (Studies C08-002A/B, C08-003A/B, and C10-004), one in pediatric and adolescent patients (Study C10-003), and one retrospective study (Study C09-001r). The data described below were derived from 78 adult and adolescent patients with aHUS in Studies C08-002A/B, C08-003A/B and C10-004. All patients received the recommended dosage of eculizumab. Median exposure was 67 weeks (range: 2-145 weeks). Table 6 summarizes all adverse events reported in at least 10% of patients in Studies C08-002A/B, C08-003A/B and C10-004 combined. Table 6: Per Patient Incidence of Adverse Events in 10% or More Adult and Adolescent Patients Enrolled in Studies C08-002A/B, C08-003A/B and C10-004 Separately and in Total Number (%) of Patients C08-002A/B (N = 17) C08-003A/B (N = 20) C10-004 (N = 41) Total (N = 78) Vascular Disorders Hypertension includes the preferred terms hypertension, accelerated hypertension, and malignant hypertension. 10 (59) 9 (45) 7 (17) 26 (33) Hypotension 2 (12) 4 (20) 7 (17) 13 (17) Infections and Infestations Bronchitis 3 (18) 2 (10) 4 (10) 9 (12) Nasopharyngitis 3 (18) 11 (55) 7 (17) 21 (27) Gastroenteritis 3 (18) 4 (20) 2 (5) 9 (12) Upper respiratory tract infection 5 (29) 8 (40) 2 (5) 15 (19) Urinary tract infection 6 (35) 3 (15) 8 (20) 17 (22) Gastrointestinal Disorders Diarrhea 8 (47) 8 (40) 12 (32) 29 (37) Vomiting 8 (47) 9 (45) 6 (15) 23 (30) Nausea 5 (29) 8 (40) 5 (12) 18 (23) Abdominal pain 3 (18) 6 (30) 6 (15) 15 (19) Nervous System Disorders Headache 7 (41) 10 (50) 15 (37) 32 (41) Blood and Lymphatic System Disorders Anemia 6 (35) 7 (35) 7 (17) 20 (26) Leukopenia 4 (24) 3 (15) 5 (12) 12 (15) Psychiatric Disorders Insomnia 4 (24) 2 (10) 5 (12) 11 (14) Renal and Urinary Disorders Renal Impairment 5 (29) 3 (15) 6 (15) 14 (18) Proteinuria 2 (12) 1 (5) 5 (12) 8 (10) Respiratory, Thoracic and Mediastinal Disorders Cough 4 (24) 6 (30) 8 (20) 18 (23) General Disorders and Administration Site Conditions Fatigue 3 (18) 4 (20) 3 (7) 10 (13) Peripheral edema 5 (29) 4 (20) 9 (22) 18 (23) Pyrexia 4 (24) 5 (25) 7 (17) 16 (21) Asthenia 3 (18) 4 (20) 6 (15) 13 (17) Eye Disorder 5 (29) 2 (10) 8 (20) 15 (19) Metabolism and Nutrition Disorders Hypokalemia 3 (18) 2 (10) 4 (10) 9 (12) Neoplasms benign, malignant, and unspecified (including cysts and polyps) 1 (6) 6 (30) 1 (20) 8 (10) Skin and Subcutaneous Tissue Disorders Rash 2 (12) 3 (15) 6 (15) 11 (14) Pruritus 1 (6) 3 (15) 4 (10) 8 (10) Musculoskeletal and Connective Tissue Disorders Arthralgia 1 (6) 2 (10) 7 (17) 10 (13) Back pain 3 (18) 3 (15) 2 (5) 8 (10) In Studies C08-002A/B, C08-003A/B and C10-004 combined, 60% (47/78) of patients experienced a serious adverse event (SAE). The most commonly reported SAEs were infections (24%), hypertension (5%), chronic renal failure (5%), and renal impairment (5%). Five patients discontinued eculizumab due to adverse events; three due to worsening renal function, one due to new diagnosis of Systemic Lupus Erythematosus, and one due to meningococcal meningitis. Study C10-003 included 22 pediatric and adolescent patients, of which 18 patients were less than 12 years of age. All patients received the recommended dosage of eculizumab. Median exposure was 44 weeks (range: 1 dose-87 weeks). Table 7 summarizes all adverse events reported in at least 10% of patients enrolled in Study C10-003. Table 7: Per Patient Incidence of Adverse Reactions in 10% or More Patients Enrolled in Study C10-003 1 month to < 12 yrs (N = 18) Total (N = 22) Eye Disorders 3 (17) 3 (14) Gastrointestinal Disorders Abdominal pain 6 (33) 7 (32) Diarrhea 5 (28) 7 (32) Vomiting 4 (22) 6 (27) Dyspepsia 0 3 (14) General Disorders and Administration Site Conditions Pyrexia 9 (50) 11 (50) Infections and Infestations Upper respiratory tract infection 5 (28) 7 (32) Nasopharyngitis 3 (17) 6 (27) Rhinitis 4 (22) 4 (18) Urinary Tract infection 3 (17) 4 (18) Catheter site infection 3 (17) 3 (14) Musculoskeletal and Connective Tissue Disorders Muscle spasms 2 (11) 3 (14) Nervous System Disorders Headache 3 (17) 4 (18) Renal and Urinary Disorders 3 (17) 4 (18) Respiratory, Thoracic and Mediastinal Disorders Cough 7 (39) 8 (36) Oropharyngeal pain 1 (6) 3 (14) Skin and Subcutaneous Tissue Disorders Rash 4 (22) 4 (18) Vascular Disorders Hypertension 4 (22) 4 (18) In Study C10-003, 59% (13/22) of patients experienced a serious adverse event (SAE). The most commonly reported SAEs were hypertension (9%), viral gastroenteritis (9%), pyrexia (9%), and upper respiratory infection (9%). One patient discontinued eculizumab due to an adverse event (severe agitation). Analysis of retrospectively collected adverse event data from pediatric and adult patients enrolled in Study C09-001r (N = 30) revealed a safety profile that was similar to that which was observed in the two prospective studies. Study C09-001r included 19 pediatric patients less than 18 years of age. Overall, the safety of eculizumab in pediatric patients with aHUS enrolled in Study C09-001r appeared similar to that observed in adult patients. The most common (≥ 15%) adverse events occurring in pediatric patients are presented in Table 8. Table 8: Adverse Reactions Occurring in at Least 15% of Patients Less than 18 Years of Age Enrolled in Study C09-001r Number (%) of Patients < 2 yrs (N = 5) 2 to < 12 yrs (N = 10) 12 to < 18 yrs (N = 4) Total (N = 19) General Disorders and Administration Site Conditions Pyrexia 4 (80) 4 (40) 1 (25) 9 (47) Gastrointestinal Disorders Diarrhea 1 (20) 4 (40) 1 (25) 6 (32) Vomiting 2 (40) 1 (10) 1 (25) 4 (21) Infections and Infestations Upper respiratory tract infection includes the preferred terms upper respiratory tract infection and nasopharyngitis. 2 (40) 3 (30) 1 (25) 6 (32) Respiratory, Thoracic and Mediastinal Disorders Cough 3 (60) 2 (20) 0 (0) 5 (26) Nasal congestion 2 (40) 2 (20) 0 (0) 4 (21) Cardiac Disorders Tachycardia 2 (40) 2 (20) 0 (0) 4 (21) Generalized Myasthenia Gravis (gMG) Adults In a 26-week placebo-controlled trial evaluating the effect of eculizumab for the treatment of adult patients with gMG (Study ECU-MG-301), 62 patients received eculizumab at the recommended dosage regimen and 63 patients received placebo [see Clinical Studies (14.3) ] . Patients were 19 to 79 years of age, and 66% were female. Table 9 displays the most common adverse reactions from Study ECU-MG-301 that occurred in ≥ 5% of eculizumab-treated patients and at a greater frequency than on placebo. Table 9: Adverse Reactions Reported in 5% or More of Eculizumab-Treated Patients in Study ECU-MG-301 and at a Greater Frequency than in Placebo-Treated Patients Eculizumab (N = 62) N(%) Placebo (N = 63) N(%) Gastrointestinal Disorders Abdominal pain 5 (8) 3 (5) General Disorders and Administration Site Conditions Peripheral edema 5 (8) 3 (5) Pyrexia 4 (7) 2 (3) Infections and Infestations Herpes simplex virus infections 5 (8) 1 (2) Injury, Poisoning, and Procedural Complications Contusion 5 (8) 2 (3) Musculoskeletal and Connective Tissue Disorders Musculoskeletal pain 9 (15) 5 (8) The most common adverse reactions (≥ 10%) that occurred in eculizumab-treated patients in the long-term extension to Study ECU-MG-301, Study ECU-MG-302, and that are not included in Table 9 were headache (26%), nasopharyngitis (24%), diarrhea (15%), arthralgia (12%), upper respiratory tract infection (11%), and nausea (10%). Neuromyelitis Optica Spectrum Disorder (NMOSD) In a placebo-controlled trial evaluating the effect of eculizumab for the treatment of NMOSD (NMOSD Study 1), 96 patients received eculizumab at the recommended dosage regimen and 47 patients received placebo [see Clinical Studies (14.4) ] . Patients were 19 to 75 years of age (mean 44 years of age), and 91% were female. Table 10 displays the most common adverse reactions from NMOSD Study 1 that occurred in ≥ 5% of eculizumab-treated patients and at a greater frequency than on placebo. Table 10: Adverse Reactions Reported in 5% or More of Eculizumab-Treated Patients in NMOSD Study 1 and at a Greater Frequency than in Placebo-Treated Patients Eculizumab (N = 96) N (%) Placebo (N = 47) N (%) Events/Patients 1295/88 617/45 Blood and lymphatic system disorders Leukopenia 5 (5) 1 (2) Lymphopenia 5 (5) 0 (0) Eye disorders Cataract 6 (6) 2 (4) Gastrointestinal disorders Diarrhea 15 (16) 7 (15) Constipation 9 (9) 3 (6) General disorders and administration site conditions Asthenia 5 (5) 1 (2) Infections and infestations Upper respiratory tract infection 28 (29) 6 (13) Nasopharyngitis 20 (21) 9 (19) Influenza 11 (11) 2 (4) Pharyngitis 10 (10) 3 (6) Bronchitis 9 (9) 3 (6) Conjunctivitis 9 (9) 4 (9) Cystitis 8 (8) 1 (2) Hordeolum 7 (7) 0 (0) Sinusitis 6 (6) 0 (0) Cellulitis 5 (5) 1 (2) Injury, poisoning and procedural complications Contusion 10 (10) 2 (4) Metabolism and nutrition disorders Decreased appetite 5 (5) 1 (2) Musculoskeletal and connective tissue disorders Back pain 14 (15) 6 (13) Arthralgia 11 (11) 5 (11) Musculoskeletal pain 6 (6) 0 (0) Muscle spasms 5 (5) 2 (4) Nervous system disorders Dizziness 14 (15) 6 (13) Paraesthesia 8 (8) 3 (6) Respiratory, thoracic and mediastinal disorders Oropharyngeal pain 7 (7) 2 (4) Skin and subcutaneous tissue disorders Alopecia 5 (5) 2 (4) 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of eculizumab products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to eculizumab products exposure. Adverse Reactions from Postmarketing Spontaneous Reports Fatal or serious infections: Neisseria gonorrhoeae, Neisseria meningitidis, Neisseria sicca/subflava, Neisseria spp unspecified. Cases of cholestatic or mixed pattern liver injury with increased serum liver enzymes and bilirubin levels have been reported in adult and pediatric patients with aHUS who were treated with eculizumab products. These events occurred within 3 to 27 days after starting treatment. The median time to resolution (or return to baseline) was approximately 3 weeks.

<table width="85%"><caption>Table 5: Adverse Reactions Reported in 5% or More of Eculizumab Treated Patients with PNH and Greater than Placebo in the Controlled Clinical Study</caption><col width="50%" align="left" valign="top"/><col width="25%" align="center" valign="top"/><col width="25%" align="center" valign="top"/><thead><tr><th styleCode="Lrule" align="left" valign="top">Reaction</th><th>Eculizumab (N = 43) N (%)</th><th styleCode="Rrule">Placebo (N = 44) N (%)</th></tr></thead><tbody><tr><td styleCode="Lrule">Headache</td><td>19 (44)</td><td styleCode="Rrule">12 (27)</td></tr><tr><td styleCode="Lrule">Nasopharyngitis</td><td>10 (23)</td><td styleCode="Rrule">8 (18)</td></tr><tr><td styleCode="Lrule">Back pain</td><td>8 (19)</td><td styleCode="Rrule">4 (9)</td></tr><tr><td styleCode="Lrule">Nausea</td><td>7 (16)</td><td styleCode="Rrule">5 (11)</td></tr><tr><td styleCode="Lrule">Fatigue</td><td>5 (12)</td><td styleCode="Rrule">1 (2)</td></tr><tr><td styleCode="Lrule">Cough</td><td>5 (12)</td><td styleCode="Rrule">4 (9)</td></tr><tr><td styleCode="Lrule">Herpes simplex infections</td><td>3 (7)</td><td styleCode="Rrule">0</td></tr><tr><td styleCode="Lrule">Sinusitis</td><td>3 (7)</td><td styleCode="Rrule">0</td></tr><tr><td styleCode="Lrule">Respiratory tract infection</td><td>3 (7)</td><td styleCode="Rrule">1 (2)</td></tr><tr><td styleCode="Lrule">Constipation</td><td>3 (7)</td><td styleCode="Rrule">2 (5)</td></tr><tr><td styleCode="Lrule">Myalgia</td><td>3 (7)</td><td styleCode="Rrule">1 (2)</td></tr><tr><td styleCode="Lrule">Pain in extremity</td><td>3 (7)</td><td styleCode="Rrule">1 (2)</td></tr><tr><td styleCode="Lrule">Influenza-like illness</td><td>2 (5)</td><td styleCode="Rrule">1 (2)</td></tr></tbody></table>

<table width="75%"><caption>Table 6: Per Patient Incidence of Adverse Events in 10% or More Adult and Adolescent Patients Enrolled in Studies C08-002A/B, C08-003A/B and C10-004 Separately and in Total</caption><col width="40%" align="left" valign="top"/><col width="15%" align="center" valign="top"/><col width="15%" align="center" valign="top"/><col width="15%" align="center" valign="top"/><col width="15%" align="center" valign="top"/><thead><tr><th styleCode="Lrule"/><th colspan="4" align="center" styleCode="Rrule">Number (%) of Patients</th></tr><tr><th styleCode="Lrule"/><th>C08-002A/B (N = 17)</th><th>C08-003A/B (N = 20)</th><th>C10-004 (N = 41)</th><th styleCode="Rrule">Total (N = 78)</th></tr></thead><tbody><tr><td styleCode="Lrule Rrule" colspan="5"><content styleCode="bold">Vascular Disorders</content></td></tr><tr><td styleCode="Lrule"> Hypertension<footnote>includes the preferred terms hypertension, accelerated hypertension, and malignant hypertension.</footnote></td><td>10 (59)</td><td>9 (45)</td><td>7 (17)</td><td styleCode="Rrule">26 (33)</td></tr><tr><td styleCode="Lrule"> Hypotension</td><td>2 (12)</td><td>4 (20)</td><td>7 (17)</td><td styleCode="Rrule">13 (17)</td></tr><tr><td styleCode="Lrule Rrule" colspan="5"><content styleCode="bold">Infections and Infestations</content></td></tr><tr><td styleCode="Lrule"> Bronchitis</td><td>3 (18)</td><td>2 (10)</td><td>4 (10)</td><td styleCode="Rrule">9 (12)</td></tr><tr><td styleCode="Lrule"> Nasopharyngitis</td><td>3 (18)</td><td>11 (55)</td><td>7 (17)</td><td styleCode="Rrule">21 (27)</td></tr><tr><td styleCode="Lrule"> Gastroenteritis</td><td>3 (18)</td><td>4 (20)</td><td>2 (5)</td><td styleCode="Rrule">9 (12)</td></tr><tr><td styleCode="Lrule"> Upper respiratory tract infection</td><td>5 (29)</td><td>8 (40)</td><td>2 (5)</td><td styleCode="Rrule">15 (19)</td></tr><tr><td styleCode="Lrule"> Urinary tract infection</td><td>6 (35)</td><td>3 (15)</td><td>8 (20)</td><td styleCode="Rrule">17 (22)</td></tr><tr><td styleCode="Lrule Rrule" colspan="5"><content styleCode="bold">Gastrointestinal Disorders</content></td></tr><tr><td styleCode="Lrule"> Diarrhea</td><td>8 (47)</td><td>8 (40)</td><td>12 (32)</td><td styleCode="Rrule">29 (37)</td></tr><tr><td styleCode="Lrule"> Vomiting</td><td>8 (47)</td><td>9 (45)</td><td>6 (15)</td><td styleCode="Rrule">23 (30)</td></tr><tr><td styleCode="Lrule"> Nausea</td><td>5 (29)</td><td>8 (40)</td><td>5 (12)</td><td styleCode="Rrule">18 (23)</td></tr><tr><td styleCode="Lrule"> Abdominal pain</td><td>3 (18)</td><td>6 (30)</td><td>6 (15)</td><td styleCode="Rrule">15 (19)</td></tr><tr><td styleCode="Lrule Rrule" colspan="5"><content styleCode="bold">Nervous System Disorders</content></td></tr><tr><td styleCode="Lrule"> Headache</td><td>7 (41)</td><td>10 (50)</td><td>15 (37)</td><td styleCode="Rrule">32 (41)</td></tr><tr><td styleCode="Lrule Rrule" colspan="5"><content styleCode="bold">Blood and Lymphatic System Disorders</content></td></tr><tr><td styleCode="Lrule"> Anemia</td><td>6 (35)</td><td>7 (35)</td><td>7 (17)</td><td styleCode="Rrule">20 (26)</td></tr><tr><td styleCode="Lrule"> Leukopenia</td><td>4 (24)</td><td>3 (15)</td><td>5 (12)</td><td styleCode="Rrule">12 (15)</td></tr><tr><td styleCode="Lrule Rrule" colspan="5"><content styleCode="bold">Psychiatric Disorders</content></td></tr><tr><td styleCode="Lrule"> Insomnia</td><td>4 (24)</td><td>2 (10)</td><td>5 (12)</td><td styleCode="Rrule">11 (14)</td></tr><tr><td styleCode="Lrule Rrule" colspan="5"><content styleCode="bold">Renal and Urinary Disorders</content></td></tr><tr><td styleCode="Lrule"> Renal Impairment</td><td>5 (29)</td><td>3 (15)</td><td>6 (15)</td><td styleCode="Rrule">14 (18)</td></tr><tr><td styleCode="Lrule"> Proteinuria</td><td>2 (12)</td><td>1 (5)</td><td>5 (12)</td><td styleCode="Rrule">8 (10)</td></tr><tr><td styleCode="Lrule Rrule" colspan="5"><content styleCode="bold">Respiratory, Thoracic and Mediastinal Disorders</content></td></tr><tr><td styleCode="Lrule"> Cough</td><td>4 (24)</td><td>6 (30)</td><td>8 (20)</td><td styleCode="Rrule">18 (23)</td></tr><tr><td styleCode="Lrule Rrule" colspan="5"><content styleCode="bold">General Disorders and Administration Site Conditions</content></td></tr><tr><td styleCode="Lrule"> Fatigue</td><td>3 (18)</td><td>4 (20)</td><td>3 (7)</td><td styleCode="Rrule">10 (13)</td></tr><tr><td styleCode="Lrule"> Peripheral edema</td><td>5 (29)</td><td>4 (20)</td><td>9 (22)</td><td styleCode="Rrule">18 (23)</td></tr><tr><td styleCode="Lrule"> Pyrexia</td><td>4 (24)</td><td>5 (25)</td><td>7 (17)</td><td styleCode="Rrule">16 (21)</td></tr><tr><td styleCode="Lrule"> Asthenia</td><td>3 (18)</td><td>4 (20)</td><td>6 (15)</td><td styleCode="Rrule">13 (17)</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Eye Disorder</content></td><td>5 (29)</td><td>2 (10)</td><td>8 (20)</td><td styleCode="Rrule">15 (19)</td></tr><tr><td styleCode="Lrule Rrule" colspan="5"><content styleCode="bold">Metabolism and Nutrition Disorders</content></td></tr><tr><td styleCode="Lrule"> Hypokalemia</td><td>3 (18)</td><td>2 (10)</td><td>4 (10)</td><td styleCode="Rrule">9 (12)</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Neoplasms benign, malignant, and unspecified (including cysts and polyps)</content></td><td>1 (6)</td><td>6 (30)</td><td>1 (20)</td><td styleCode="Rrule">8 (10)</td></tr><tr><td styleCode="Lrule Rrule" colspan="5"><content styleCode="bold">Skin and Subcutaneous Tissue Disorders</content></td></tr><tr><td styleCode="Lrule"> Rash</td><td>2 (12)</td><td>3 (15)</td><td>6 (15)</td><td styleCode="Rrule">11 (14)</td></tr><tr><td styleCode="Lrule"> Pruritus</td><td>1 (6)</td><td>3 (15)</td><td>4 (10)</td><td styleCode="Rrule">8 (10) </td></tr><tr><td styleCode="Lrule Rrule" colspan="5"><content styleCode="bold">Musculoskeletal and Connective Tissue Disorders</content></td></tr><tr><td styleCode="Lrule"> Arthralgia</td><td>1 (6)</td><td>2 (10)</td><td>7 (17)</td><td styleCode="Rrule">10 (13)</td></tr><tr><td styleCode="Lrule"> Back pain</td><td>3 (18)</td><td>3 (15)</td><td>2 (5) </td><td styleCode="Rrule">8 (10)</td></tr></tbody></table>

<table width="75%"><caption>Table 7: Per Patient Incidence of Adverse Reactions in 10% or More Patients Enrolled in Study C10-003</caption><col width="50%" align="left" valign="middle"/><col width="25%" align="center" valign="middle"/><col width="25%" align="center" valign="middle"/><thead><tr><th styleCode="Lrule"/><th>1 month to &lt; 12 yrs (N = 18)</th><th styleCode="Rrule">Total (N = 22)</th></tr></thead><tbody><tr><td styleCode="Lrule"><content styleCode="bold">Eye Disorders</content></td><td>3 (17)</td><td styleCode="Rrule">3 (14) </td></tr><tr><td styleCode="Lrule Rrule" colspan="3"><content styleCode="bold">Gastrointestinal Disorders</content></td></tr><tr><td styleCode="Lrule"> Abdominal pain</td><td>6 (33) </td><td styleCode="Rrule">7 (32)</td></tr><tr><td styleCode="Lrule"> Diarrhea</td><td>5 (28)</td><td styleCode="Rrule">7 (32)</td></tr><tr><td styleCode="Lrule"> Vomiting</td><td>4 (22)</td><td styleCode="Rrule">6 (27)</td></tr><tr><td styleCode="Lrule"> Dyspepsia</td><td>0</td><td styleCode="Rrule">3 (14)</td></tr><tr><td styleCode="Lrule Rrule" colspan="3"><content styleCode="bold">General Disorders and Administration Site Conditions </content></td></tr><tr><td styleCode="Lrule"> Pyrexia</td><td>9 (50)</td><td styleCode="Rrule">11 (50)</td></tr><tr><td styleCode="Lrule Rrule" colspan="3"><content styleCode="bold">Infections and Infestations</content></td></tr><tr><td styleCode="Lrule"> Upper respiratory tract infection</td><td>5 (28)</td><td styleCode="Rrule">7 (32)</td></tr><tr><td styleCode="Lrule"> Nasopharyngitis</td><td>3 (17)</td><td styleCode="Rrule">6 (27)</td></tr><tr><td styleCode="Lrule"> Rhinitis</td><td>4 (22) </td><td styleCode="Rrule">4 (18)</td></tr><tr><td styleCode="Lrule"> Urinary Tract infection</td><td>3 (17)</td><td styleCode="Rrule">4 (18)</td></tr><tr><td styleCode="Lrule"> Catheter site infection</td><td>3 (17)</td><td styleCode="Rrule">3 (14)</td></tr><tr><td styleCode="Lrule Rrule" colspan="3"><content styleCode="bold">Musculoskeletal and Connective Tissue Disorders </content></td></tr><tr><td styleCode="Lrule"> Muscle spasms</td><td>2 (11)</td><td styleCode="Rrule">3 (14)</td></tr><tr><td styleCode="Lrule Rrule" colspan="3"><content styleCode="bold">Nervous System Disorders </content></td></tr><tr><td styleCode="Lrule"> Headache</td><td>3 (17)</td><td styleCode="Rrule">4 (18)</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Renal and Urinary Disorders</content></td><td>3 (17)</td><td styleCode="Rrule">4 (18)</td></tr><tr><td styleCode="Lrule Rrule" colspan="3"><content styleCode="bold">Respiratory, Thoracic and Mediastinal Disorders</content></td></tr><tr><td styleCode="Lrule"> Cough</td><td>7 (39)</td><td styleCode="Rrule">8 (36)</td></tr><tr><td styleCode="Lrule"> Oropharyngeal pain</td><td>1 (6)</td><td styleCode="Rrule">3 (14)</td></tr><tr><td styleCode="Lrule Rrule" colspan="3"><content styleCode="bold">Skin and Subcutaneous Tissue Disorders</content></td></tr><tr><td styleCode="Lrule"> Rash</td><td>4 (22)</td><td styleCode="Rrule">4 (18)</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Vascular Disorders</content></td><td/><td styleCode="Rrule"/></tr><tr><td styleCode="Lrule"> Hypertension</td><td>4 (22)</td><td styleCode="Rrule">4 (18)</td></tr></tbody></table>